United States Sex Reassignment Hormone Therapy Market Insights Forecasts to 2033s
- The United States Sex Reassignment Hormone Therapy Market Size was valued at USD 1.5 Billion in 2023
- The Market Size is Growing at a CAGR of 4.0% from 2023 to 2033.
- The United States Sex Reassignment Hormone Therapy Market Size is Expected to Reach USD 2.22 Billion by 2033.
Get more details on this report -
The United States Sex Reassignment Hormone Therapy Market size is Expected to Reach USD 2.22 Billion by 2033, at a CAGR of 4.0% during the forecast period 2023 to 2033.
Hormone therapy is a less expensive option than surgical procedures for gender-affirming care. While it provides a cost-effective solution, it requires long-term commitment and consistent use to achieve the desired results. Furthermore, several drugs used in gender-affirming care are prescribed off-label in the United States. Puberty blockers are the first line of treatment for people seeking sex reassignment, followed by the administration of estrogen or testosterone depending on whether the transition is male-to-female (MTF) or female-to-male (FTM). This market has grown and evolved significantly over time, reflecting increased societal awareness and acceptance of gender diversity. Sex reassignment hormone therapy, also known as HRT (Hormone Replacement Therapy), is an essential part of the gender transition process for many transgender people, and the market's growth reflects the ongoing expansion of transgender healthcare services in the United States. The market includes a variety of pharmaceutical products and medical services aimed at assisting transgender people in matching their physical characteristics to their gender identities. This includes administering hormones like estrogen and testosterone to promote secondary sex characteristics that correspond to a person's gender identity. The United States has a diverse range of healthcare providers, clinics, and specialized centers that provide hormone therapy services, demonstrating the country's commitment to transgender healthcare.
This research report categorizes the market for the United States sex reassignment hormone therapy market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States sex reassignment hormone therapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United States sex reassignment hormone therapy market.
United States Sex Reassignment Hormone Therapy Market Report Coverage
|Market Size in 2023:
|USD 1.5 Billion
|2023 - 2033
|Forecast Period 2023 - 2033 CAGR:
|2033 Value Projection:
|USD 2.22 Billion
|Historical Data for:
|2019 - 2022
|No. of Pages:
|Tables, Charts & Figures:
|By Gender Transition, By Type, By Distribution Channel and COVID-19 Impact Analysis.
|Viatris Inc., AbbVie Inc., ASCEND Therapeutics US, LLC., Pfizer Inc., Eli Lilly and Company, Novartis AG, Endo International plc., and Others
|Pitfalls & Challenges:
|COVID-19 Empact, Challenge, Future, Growth, & Analysis
Get more details on this report -
Increased awareness and acceptance have become powerful catalysts in propelling the United States sex reassignment hormone therapy market to new heights, with one of the most significant drivers of this change being the increased visibility of transgender people in mainstream media, politics, and public discourse. Growing medical expertise is also an essential factor that is significantly boosting the United States sex reassignment hormone therapy market. The increased number of healthcare providers with specialized knowledge in transgender healthcare ensures that transgender individuals have access to more experienced and knowledgeable practitioners. Furthermore, research and development efforts have played a pivotal role in boosting the United States sex reassignment hormone therapy (HRT) market. One of the key contributions of research and development to the HRT market is the development of safer and more effective hormones.
The United States has made significant progress in improving access to transgender healthcare, but one formidable challenge remains cost and insurance barriers. While significant progress has been made in improving access to transgender healthcare in the United States, one pressing challenge that keeps hampering the sex reassignment hormone therapy (HRT) market is limited access in underserved areas.
- In 2023, the male-to-female segment accounted for the largest revenue share over the forecast period.
Based on gender transition, the United States sex reassignment hormone therapy market is segmented into male-to-female, and female-to-male. Among these, the male-to-female segment has the largest revenue share over the forecast period. Studies and data indicate that MTF transitions are more common than FTM transitions. This increased prevalence results in a larger pool of people seeking MTF hormone therapy, which raises demand for these services. MTF individuals, who are frequently assigned male at birth, usually require estrogen and anti-androgen medications to develop secondary female sex characteristics such as breast development and softer skin. Government support is also driving the market. Thus, government assistance in the form of medicare coverage and an increase in the number of gender confirmation surgeries are expected to drive market growth. Since the growing awareness of the therapies and the availability of advanced hormone therapies in the United States.
- In 2023, the estrogen segment is witnessing significant growth over the forecast period.
Based on type, the United States sex reassignment hormone therapy market is segmented into puberty blockers, estrogen, and testosterone. Among these, the estrogen segment is witnessing significant growth over the forecast period. Estrogen drugs are the primary hormone treatment for transgender women seeking sex reassignment. The prescription of estrogens to transgender women or trans feminine individuals (MTF) is similar to hormone replacement therapy for postmenopausal women, albeit at slightly higher doses. Additionally, testosterone is a lucrative market segment. It is frequently used to produce masculinizing effects in transgender men. The availability of a diverse range of product forms based on individual compatibility drives product adoption in the space. Individuals who were born male and wish to transition to female typically require estrogen therapy to develop secondary female sex characteristics such as breast development, softer skin, and fat redistribution. Many transgender people seeking MTF transition believe that estrogen therapy is medically necessary to effectively treat gender dysphoria. This medical necessity contributes to the high demand for these treatments.
- In 2023, the retail pharmacy segment accounted for the largest revenue share over the forecast period.
Based on the distribution channel, the United States sex reassignment hormone therapy market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the retail pharmacy segment has the largest revenue share over the forecast period. The segment's growth is attributed to increased awareness of the availability of hormone therapy products, combined with the convenience and accessibility of retail pharmacies, which make it easier for people to obtain hormone therapy prescriptions and related medications.
The report offers the appropriate analysis of the key organizations/companies involved within the United States sex reassignment hormone Therapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Viatris Inc.
- AbbVie Inc.
- ASCEND Therapeutics US, LLC.
- Pfizer Inc.
- Eli Lilly and Company
- Novartis AG
- Endo International plc.
Key Target Audience
- Market Players
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In January 2022, Endo International plc unveiled the results of a population pharmacokinetic (PK) modeling and simulation analysis. This study investigated the possibility of adaptable dosing of AVEED (testosterone undecanoate) in males with hypogonadism, with potential benefits for gender-affirming treatments.
This study forecasts revenue at regional, and country levels from 2022 to 2033. Spherical Insights has segmented the United States Sex Reassignment Hormone Therapy Market based on the below-mentioned segments:
United States Sex Reassignment Hormone Therapy Market, By Gender Transition
United States Sex Reassignment Hormone Therapy Market, By Type
- Puberty Blockers
United States Sex Reassignment Hormone Therapy Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Need help to buy this report?